Impact of tumor site on bevacizumab (BEV) efficacy in metastatic colorectal cancer (mCRC)

被引：0
|
作者：
Wong, Hui-Li
Field, Kathryn Maree
Lomax, Anna
Tacey, Mark
Shapiro, Jeremy David
McKendrick, Joseph James
Zlmet, Allan Solomon
Yip, Desmond
Nott, Louise M.
Jennens, Ross
Richardson, Gary Edward
Tie, Jeanne
Kosmider, Suzanne
Parente, Phillip
Lim, Lionel
Cooray, Prasad
Tran, Ben
Desai, Jayesh
Wong, Rachel
Gibbs, Peter
机构：
[1] Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia
[2] Royal Melbourne Hosp, Melbourne, Vic, Australia
[3] Eastern Hlth, Dept Med Oncol, Melbourne, Vic, Australia
[4] Univ Melbourne, Melbourne Epictr, Melbourne, Vic, Australia
[5] Cabrini Hosp, Melbourne, Vic, Australia
[6] Eastern Hlth, Box Hill Hosp, Melbourne, Vic, Australia
[7] Epworth Med Fdn, Melbourne, Vic, Australia
[8] Canberra Hosp, Canberra, ACT, Australia
[9] Australian Natl Univ, ANU Med Sch, Canberra, ACT, Australia
[10] Royal Hobart Hosp, Hobart, Tas, Australia
[11] Western Hosp, Melbourne, Vic, Australia
[12] Monash Univ, Dept Med Oncol, Fac Med Nursing & Hlth Sci, Eastern Hlth Clin Sch, Clayton, Vic 3800, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.e14558
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14558
引用
收藏
页数：1
相关论文
共 50 条
  • [1] IMPACT OF TUMOUR SITE ON BEVACIZUMAB EFFICACY IN METASTATIC COLORECTAL CANCER (mCRC)
    Wong, H.
    Field, K.
    Lomax, A.
    Tacey, M.
    Shapiro, J.
    McKendrick, J.
    Zimet, A.
    Yip, D.
    Nott, L.
    Jennens, R.
    Richardson, G.
    Tie, J.
    Kosmider, S.
    Parente, P.
    Lim, L.
    Cooray, P.
    Tran, B.
    Desai, J.
    Wong, R.
    Gibbs, P.
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 46 - 46
  • [2] Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer
    Wong, Hui-li
    Lee, Belinda
    Field, Kathryn
    Lomax, Anna
    Tacey, Mark
    Shapiro, Jeremy
    McKendrick, Joe
    Zimet, Allan
    Yip, Desmond
    Nott, Louise
    Jennens, Ross
    Richardson, Gary
    Tie, Jeanne
    Kosmider, Suzanne
    Parente, Phillip
    Lim, Lionel
    Cooray, Prasad
    Ben Tran
    Desai, Jayesh
    Wong, Rachel
    Gibbs, Peter
    [J]. CLINICAL COLORECTAL CANCER, 2016, 15 (02) : E9 - E15
  • [3] Bevacizumab (bev) for metastatic colorectal cancer (mCRC): A global cost-effectiveness analysis
    Goldstein, Daniel A.
    Chen, Qiushi
    Ayer, Turgay
    Chan, Kelvin K.
    Virik, Kiran
    Hammerman, Ariel
    Brenner, Baruch
    Flowers, Christopher
    Hall, Peter
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Prognostic impact of primary tumor site location in metastatic colorectal cancer (mCRC).
    Matos, Ignacio
    Ortiz, Carolina
    Elez, Elena
    Argiles, Guillem
    Grasselli, Julieta
    Macarulla, Teresa
    Capdevila, Jaume
    Alsina, Maria
    Sauri, Tamara
    Hierro, Cinta
    Verdaguer, Helena
    Sanz-Garcia, Enrique
    Maria Martinez, Ana
    Espin, Eloy
    Dopazo, Cristina
    Landolfi, Stefania
    Nuciforo, Paolo
    Vivancos, Ana
    Dienstmann, Rodrigo
    Tabernero, Josep
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [5] Impact of Primary Tumor Localization on the Efficacy of Bevacizumab in Metastatic Colorectal Cancer
    Jordan, Frank
    Grundmann, Nina
    Schenkirsch, Gerhard
    Maerkl, Bruno
    Messmann, Helmuth
    Anthuber, Matthias
    Schmid, Christoph
    Trepel, Martin
    [J]. ANTICANCER RESEARCH, 2018, 38 (09) : 5539 - 5546
  • [6] Efficacy outcomes by age from 5 observational or phase-4 studies of bevacizumab (Bev) in metastatic colorectal cancer (mCRC)
    Hubbard, J.
    Grothey, A.
    Van Cutsem, E.
    Hurwitz, H.
    Kozloff, M. F.
    Bekaii-Saab, T.
    Bennouna, J.
    Zafar, Y.
    Revil, C.
    Sommer, N.
    Srock, S.
    Arnold, D.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 42 - 43
  • [7] The role of immune system on the efficacy of bevacizumab in patients with metastatic colorectal cancer (mCRC)
    Akbulut, H.
    Ocal, M.
    Sonugur, G.
    Akay, B.
    Babahan, C.
    Abgarmi, S. Abdi
    Demirkazik, A.
    Icli, F.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [8] Impact of bevacizumab (bev) on overall survival (OS) in patients (pts) with metastatic colorectal cancer (MCRC): A population-based study
    Renouf, D. J.
    Lim, H. J.
    Speers, C.
    Villa, D.
    Gill, S.
    Blanke, C. D.
    O'Reilly, S. E.
    Kennecke, H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Real-world treatment patterns and outcomes associated with bevacizumab (bev) in metastatic colorectal cancer (mCRC).
    Saverno, Kimberly
    Walker, Mark S.
    Hennessy, Daniel
    Dhawan, Ravinder
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] BASELINE LEVELS OF CIRCULATING ANGIOGENIC FACTORS IN METASTATIC COLORECTAL CANCER PTS (MCRC) TREATED WITH BEVACIZUMAB (BEV)
    Martinetti, A.
    Bajetta, E.
    Dibartolomeo, M.
    Dotti, K. F.
    Bianchi, F.
    Sottotetti, E.
    Gevorgyan, A.
    Celio, L.
    Fossile, E.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 66 - 66
12345